Science & Technology
Science and Technology
Science and Technology
Tue, July 20, 2010
Mon, July 19, 2010
Phase Forward to Lead Sessions at CDISC Interchange Japan 2010
TOKYO--([ BUSINESS WIRE ])--Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, will participate at [ CDISC Interchange Japan 2010 ], July 20-23 at the Toshi Center Hotel in Tokyo.
"Define.XML - Ita™s Not Just for Submissions Any More"
At CDISC Interchange Japan, company representatives will lead four sessions on key industry data standards and drug safety related issues:
Who: Robbert P. van Manen, Senior Technical Solutions Consultant, Phase Forward | |||
What:aDefine.XML - Ita™s Not Just for Submissions Any Morea | |||
When: Tuesday, July 20, 3:30 a" 5:00 p.m. JST (Japan Standard Time) | |||
Who: Robbert P. van Manen, Senior Technical Solutions Consultant, Phase Forward | |||
What:aDoing More with SDTM a" Safety Signal Detection on Clinical Trial Dataa | |||
When: Wednesday, July 21, 9:00 a" 10:45 a.m. JST | |||
Who: Joerg Dillert, Principal Consultant, Phase Forward | |||
What:aE2B under the Umbrella of HL7 and BRIDG: Looking To the Future of Data Integrations between Pharmacovigilance (E2B) and Clinical Data Managementa | |||
When: Wednesday, July 21, 9:00 a" 10:45 a.m. JST | |||
Who: Herve Ouambo, Principal Technical Consultant, Phase Forward | |||
What:aSimplifying Trial Data Extraction with CDISC ODM as a Web Service Interfacea | |||
When: Wednesday, July 21, 3:45 a" 4:45 p.m. JST | |||
Phase Forward will also be exhibiting booth #7 at the CDISC Interchange Japan 2010. Members of the media interested in speaking with Phase Forward should contact Maria Sumner at +44 1628 640743 or [ maria.sumner@phaseforward.com ] or Juli Greenwood at 781-672-3137 or [ jgreenwood@chenpr.com ].
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forwarda™s products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 300 organizations and regulatory agencies worldwide including: AstraZeneca, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and Drug Administration, GlaxoSmithKline, Harvard Clinical Research Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL International, Procter & Gamble, Quintiles, sanofi-aventis, Schering-Plough Research Institute, Servier, SGS, Tibotec and the U.K. Medicines and Healthcare Products Regulatory Agency. Additional information about Phase Forward is available at [ www.phaseforward.com ].
